We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-31.07%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$364M
AUM Growth
-$185M
Cap. Flow
+$8.2M
Cap. Flow %
2.25%
Top 10 Hldgs %
90.27%
Holding
20
New
–
Increased
5
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.21M
2
NERV icon
Minerva Neurosciences
NERV
+$2.68M
3
CMRX
Chimerix, Inc.
CMRX
+$1.17M
4
TECX
Tectonic Therapeutic
TECX
+$1.1M
5
TARA icon
Protara Therapeutics
TARA
+$41K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$86.1M 23.65%
4,104,140
– –
PRNB
2
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$71.9M 19.74%
2,625,713
– –
APTX
3
DELISTED
Aptinyx Inc. Common Stock
APTX
$54.4M 14.94%
3,290,079
– –
STIM icon
4
Neuronetics
STIM
$120M
$29.9M 8.2%
1,543,115
– –
ARVN icon
5
Arvinas
ARVN
$518M
$29.3M 8.05%
2,283,048
– –
WVE icon
6
Wave Life Sciences
WVE
$1.12B
$17.9M 4.91%
425,429
– –
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.58B
$12.7M 3.49%
444,708
– –
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.4M 3.13%
900,501
– –
COGT icon
9
Cogent Biosciences
COGT
$6.79B
$7.9M 2.17%
448,886
– –
ITRM
10
DELISTED
Iterum Therapeutics
ITRM
$7.3M 2%
97,087
– –
SRRA
11
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.63M 1.82%
125,511
– –
AFMD
12
DELISTED
Affimed
AFMD
$5.6M 1.54%
180,000
– –
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.86B
$5.03M 1.38%
167,700
– –
TECX
14
Tectonic Therapeutic
TECX
$573M
$3.59M 0.99%
17,963
+3,600
+25% +$1.1M
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
$3.47M 0.95%
1,350,000
+350,000
+35% +$1.17M
TARA icon
16
Protara Therapeutics
TARA
$226M
$3.46M 0.95%
38,080
+580
+2% +$41K
ARAV
17
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.42M 0.94%
970,659
+557,592
+135% +$3.21M
NERV icon
18
Minerva Neurosciences
NERV
$188M
$2.85M 0.78%
52,913
+36,663
+226% +$2.68M
PDSB icon
19
PDS Biotechnology
PDSB
$38.1M
$753K 0.21%
117,243
– –
AVEO
20
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$643K 0.18%
40,212
– –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q4 2018 Portfolio in Review

As of Q4 2018, New Leaf Venture Partners held 20 positions worth $364M, down 34% from $550M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Trading was light in Q4 2018: portfolio turnover was 0%. New Leaf Venture Partners opened no new positions and made no exits, leaving the 20-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners added most to Aravive, Inc. Common Stock in Q4 2018, an estimated $3.21M increase.
  • New Leaf Venture Partners's ten largest holdings make up 90% of its $364M portfolio in Q4 2018.
  • New Leaf Venture Partners opened 0 new positions and closed 0 in Q4 2018.
  • New Leaf Venture Partners's portfolio value fell 34% quarter-over-quarter to $364M.

Based on New Leaf Venture Partners's 13F filing for Q4 2018, filed 13 Feb 2019.